Ilium Meloxicam Injection
MELOXICAM is a non-steroidal anti-inflammatory drug (NSAID) derived from oxicam. MELOXICAM acts by inhibition of prostaglandin synthesis, exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue.
Dogs – For the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders and reduction of
postoperative pain and inflammation following orthopaedic and soft tissue surgery.
Cats – Reduction of pain after surgery and management of febrile conditions in combination with appropriate antibiotics.
Directions for use
Dogs – Musculoskeletal disorders: 0.2mg MELOXICAM/kg b.w. s.c. (0.4mL/10kg b.w.). Continue treatment using MELOXICAM Oral Suspension (1.5mg/mL) using 0.1mg MELOXICAM/kg b.w.,
24 hours after administration of initial injection
Reduction of post operative pain: 0.2mg MELOXICAM/kg b.w.(0.4mL/10kg b.w.) i.v. or s.c. before surgery (ie at the time of induction of anaesthesia)
Cats – Reduction of post operative pain: 0.3mg MELOXICAM/kg b.w.(0.06mL/kg b.w.) s.c. before surgery (i.e. at the time of induction of anaesthesia)
Management of febrile
conditions – 0.3mg MELOXICAM/kg b.w.(0.06mL/kg b.w.) s.c.
Injection 10mL, 20mL multidose vial
Each mL contains 5mg Meloxicam.
DO NOT use in pregnant or lactating animals. DO NOT use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders or where there is evidence of individual hypersensitivity to the product. As for all NSAIDs use in an animal less that 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided careful clinical management
may be necessary.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete
for binding and thus lead to toxic effects. MELOXICAM must not be administered in conjunction with other NSAIDs or glucocorticosteriods. Concurrent administration of potential nephrotoxic drugs should be avoided.
Pre-treatment with other anti-inflammatory drugs prior to the use of MELOXICAM may result in additional or increased adverse effect and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with MELOXICAM injection. The treatment-free period however should take into account the pharmacokinetic properties of the drugs previously used.
Parenteral administration of MELOXICAM injection is tolerated without local adverse reactions. Typical adverse reaction of NSAIDs include: loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy. These side effects are in most cases transient and disappear following termination of treatment, but in rare cases may be serious.
Hypovolaemia or hypotension should be corrected prior to use of the product.
Store below 25ºC (air conditioning). Discard product not used within 28 days of first broaching the container.